CAS: 89226-50-6; 3-(2-(4-Benzhydrylpiperazin-1-yl)Ethyl) 5-Methyl 2,6-Dimethyl-4-(3-Nitrophenyl)-1,4-Dihydropyridine-3,5-Dicarboxylate

该化合物是二氢类的钙管阻塞器,主要用于高血压管理,有选择地抑制血管滑动肌肉中的L型钙管,导致血管通气和减少外围抗药性. 马尼迪平的一个主要优势是其行动持续时间长,允许每天一次施用并持续控制血压.它表现出高度的血管选择性,最大限度地减少直接心脏影响,如心肌梗塞.此外,曼尼迪平显示出肾脏保护性能,使其适合高血压病人的心律功能,使其适合高血压性肾功能障碍.它的亲脂性有助于持续组织渗透和逐渐开始行动,降低突然减退的风险.

结构式图片

欧盟法规

REACH注册C&L通报

上下游产品

3-nitro-benzaldehyde 2-(4-diphenylmethyl-1-piperazinyl)ethyl acetoacetate methyl 3-amin°Crotonate 2-(4-diphenylmethyl-1-piperazinyl)ethyl 2-(3-nitrobenzylidene)acetoacetateManidipine dihydr°Chloride (S)-Manidipine (R)-Manidipine

合成工艺路线路线简述

  • 合成目标产物 Manidipine 主要起始原料 1-Benzhydrylpiperazine
  • 39562-17-9 + 90096-33-6 = 89226-50-6
    反应条件:1.1 Solvents: Isopropanol
    标题:New 1,4-Dihydropyridine Derivatives With Potent And Long-Lasting Hypotensive Effect
    作者:Meguro,Kanji; Aizawa,Masahiro; Sohda,Takashi; Kawamatsu,Yutaka; Nagaoka,Akinobu
    参考文献:Chemical & Pharmaceutical Bulletin 日期:1985 卷标:33(9) 页码:3787-97
Manidipine Dihydrochloride置于sodium Hydroxide体系中,用 水 作为反应溶剂,以98%的收率获得产物马尼地平
参考文献:一种(S)-马尼地平的制备方法
标题:一种(S)-马尼地平的制备方法
摘要:本发明涉及一种(S)‑马尼地平的制备方法.具体而言,本发明以消旋的马尼地平游离碱为原料,利用拆分剂,采用化学成盐析晶法,得到光学活性的(S)‑马尼地平游离碱.本发明的制备方法收率高,工艺操作简单,成本较低,适合工业化生产.

海关参考信息

专利信息


专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-7708989-B2
优先权日:1999-10-29
标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
权利人:NITROMED INC
摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

专利号:EP-3967330-A1
优先权日:2020-09-10
标 题:Methods for the synthesis of bioactivated metal nanocluster and their medical application
发明人:MARCHI VALÉRIE; CHIECHIO REGINA MARIA; EVEN-HERNANDEZ PASCALE
权利人:UNIV RENNES; CENTRE NAT RECH SCIENT; INSTITUT NAT DES SCIENCES APPLIQUEES DE RENNES; ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES
摘要:The present invention relates to a bioactivated metal nanocluster comprising a mixture of ligands linked to a fluorescent metallic nanocluster, their synthesis methods, and their medical applications.

专利号:US-7384976-B2
优先权日:2001-05-02
标 题:Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
发明人:GARVEY DAVID S
权利人:NITROMED INC
摘要:The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.
许昌恒生制药有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.xchsyy.com
电话: 0374-5692999 18837411866👤
📞许昌恒生制药有限公司 ⚠️参考联系方式

销售电话:0374-5692999 18837411866
邮箱:xccxn@xchsyy.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig. 2011;31(7):439-53. doi: 10.2165/11589000-000000000-00000. Review. doi: 10.3265/Nefrologia.pre2010.Nov.10643. Epub 2011 Mar 15. Review. English, Spanish. doi: 10.1586/erc.10.48. Review. doi: 10.3265/Nefrologia.2009.29.3.5078.en.full. Review. Spanish. doi: 10.2165/00129784-200909030-00004. Review.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知